Comparison of trimethoprim-sulfamethoxazole and ampicillin therapy for shigellosis in ambulatory patients

John D. Nelson, Helen Kusmiesz, Lula Hinton Jackson

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

One hundred seventy-four infants and children with acute diarrhea were treated as ambulatory patients with either ampicillin (100 mg/kg/day orally in four divided doses) or trimethoprim sulfamethoxazole (10 mg TMP and 50 mg SMX/kg/day orally in two divided doses). There were 65 patients with shigellosis. Responses of those treated with TMP/SMX and of those with susceptible Shigella treated with ampicillin were comparable. Patients with resistant organisms failed to respond to ampicillin. All Shigella, including ampicillin-resistant strains, were susceptible in vitro to TMP/SMX, and patients with ampicillin-resistant strains responded favorably to treatment with TMP/SMX. TMP/SMX appears to be the best, currently available drug for the treatment of shigellosis.

Original languageEnglish (US)
Pages (from-to)491-493
Number of pages3
JournalThe Journal of Pediatrics
Volume89
Issue number3
DOIs
StatePublished - 1976

Fingerprint

Bacillary Dysentery
Sulfamethoxazole Drug Combination Trimethoprim
Ampicillin
Shigella
Thymidine Monophosphate
Therapeutics
Diarrhea
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Comparison of trimethoprim-sulfamethoxazole and ampicillin therapy for shigellosis in ambulatory patients. / Nelson, John D.; Kusmiesz, Helen; Jackson, Lula Hinton.

In: The Journal of Pediatrics, Vol. 89, No. 3, 1976, p. 491-493.

Research output: Contribution to journalArticle

@article{5b8ebca66fa543f5becf8f7e16a1ef01,
title = "Comparison of trimethoprim-sulfamethoxazole and ampicillin therapy for shigellosis in ambulatory patients",
abstract = "One hundred seventy-four infants and children with acute diarrhea were treated as ambulatory patients with either ampicillin (100 mg/kg/day orally in four divided doses) or trimethoprim sulfamethoxazole (10 mg TMP and 50 mg SMX/kg/day orally in two divided doses). There were 65 patients with shigellosis. Responses of those treated with TMP/SMX and of those with susceptible Shigella treated with ampicillin were comparable. Patients with resistant organisms failed to respond to ampicillin. All Shigella, including ampicillin-resistant strains, were susceptible in vitro to TMP/SMX, and patients with ampicillin-resistant strains responded favorably to treatment with TMP/SMX. TMP/SMX appears to be the best, currently available drug for the treatment of shigellosis.",
author = "Nelson, {John D.} and Helen Kusmiesz and Jackson, {Lula Hinton}",
year = "1976",
doi = "10.1016/S0022-3476(76)80561-6",
language = "English (US)",
volume = "89",
pages = "491--493",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Comparison of trimethoprim-sulfamethoxazole and ampicillin therapy for shigellosis in ambulatory patients

AU - Nelson, John D.

AU - Kusmiesz, Helen

AU - Jackson, Lula Hinton

PY - 1976

Y1 - 1976

N2 - One hundred seventy-four infants and children with acute diarrhea were treated as ambulatory patients with either ampicillin (100 mg/kg/day orally in four divided doses) or trimethoprim sulfamethoxazole (10 mg TMP and 50 mg SMX/kg/day orally in two divided doses). There were 65 patients with shigellosis. Responses of those treated with TMP/SMX and of those with susceptible Shigella treated with ampicillin were comparable. Patients with resistant organisms failed to respond to ampicillin. All Shigella, including ampicillin-resistant strains, were susceptible in vitro to TMP/SMX, and patients with ampicillin-resistant strains responded favorably to treatment with TMP/SMX. TMP/SMX appears to be the best, currently available drug for the treatment of shigellosis.

AB - One hundred seventy-four infants and children with acute diarrhea were treated as ambulatory patients with either ampicillin (100 mg/kg/day orally in four divided doses) or trimethoprim sulfamethoxazole (10 mg TMP and 50 mg SMX/kg/day orally in two divided doses). There were 65 patients with shigellosis. Responses of those treated with TMP/SMX and of those with susceptible Shigella treated with ampicillin were comparable. Patients with resistant organisms failed to respond to ampicillin. All Shigella, including ampicillin-resistant strains, were susceptible in vitro to TMP/SMX, and patients with ampicillin-resistant strains responded favorably to treatment with TMP/SMX. TMP/SMX appears to be the best, currently available drug for the treatment of shigellosis.

UR - http://www.scopus.com/inward/record.url?scp=0017190298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017190298&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(76)80561-6

DO - 10.1016/S0022-3476(76)80561-6

M3 - Article

VL - 89

SP - 491

EP - 493

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 3

ER -